Toward Model-Based Informed Precision Dosing of Vancomycin in Hematologic Cancer Patients: A First Step
ConclusionTo our knowledge, this study provides the first model-informed AUC-based strategy in North American hematologic cancer patients with or without HSCT. The resulting nomogram generated provides a simplified approach to improving the accuracy of initial vancomycin dosing in this population. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - December 21, 2023 Category: Drugs & Pharmacology Source Type: research
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
ConclusionsLorlatinib is a net moderate inducer of P-gp and a weak inducer of CYP2B6, CYP2C9, and UGT after steady state is achieved with daily dosing. Medications that are P-gp substrates with a narrow therapeutic window should be avoided in patients taking lorlatinib; no dose modifications are needed with substrates of CYP2B6, CYP2C9, or UGT.ClinicalTrials.gov: NCT01970865. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - December 11, 2023 Category: Drugs & Pharmacology Source Type: research
Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies
ConclusionsIn critically ill patients, total isavuconazole exposure is reduced and protein binding is highly variable. We proposed an adaptive dosing approach to enhance early treatment optimisation in this high-risk population.Clinical Trial RegistrationClinicalTrials.gov identifier: NCT04777058. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - November 28, 2023 Category: Drugs & Pharmacology Source Type: research
Population Pharmacokinetics of Digoxin in Nonagenarian Patients: Optimization of the Dosing Regimen
ConclusionsThe greatest influence on digoxin clearance came from renal function calculated by the Cockcroft –Gault equation.Vd was decreased byK. The model developed showed a precise predictive performance to be applied for therapeutic drug monitoring. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - November 28, 2023 Category: Drugs & Pharmacology Source Type: research
Impact of Key Components of Intensified Ceftaroline Dosing on Pharmacokinetic/Pharmacodynamic Target Attainment
ConclusionThe analysis calls to mind consideration of dose increases when prolonging the infusion duration in the case of low bacterial susceptibility. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - November 26, 2023 Category: Drugs & Pharmacology Source Type: research
Acknowledgement to Referees
(Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - November 22, 2023 Category: Drugs & Pharmacology Source Type: research
Digoxin Pharmacokinetics in Patients with Obesity Before and After a Gastric Bypass or a Strict Diet Compared with Normal Weight Individuals
ConclusionsChanges in digoxin pharmacokinetics following weight loss induced by a pre-operative low-energy diet and an RYGB or a strict diet (a low-energy diet plus a very-low-energy diet) were minor and unlikely to be clinically relevant. The lower systemic exposure of digoxin in patients with obesity suggests that these patients may have increased biliary excretion of digoxin possibly owing to a higher expression of P-gp in the liver. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - November 22, 2023 Category: Drugs & Pharmacology Source Type: research
Acknowledgement to Referees
(Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - November 22, 2023 Category: Drugs & Pharmacology Source Type: research
Digoxin Pharmacokinetics in Patients with Obesity Before and After a Gastric Bypass or a Strict Diet Compared with Normal Weight Individuals
ConclusionsChanges in digoxin pharmacokinetics following weight loss induced by a pre-operative low-energy diet and an RYGB or a strict diet (a low-energy diet plus a very-low-energy diet) were minor and unlikely to be clinically relevant. The lower systemic exposure of digoxin in patients with obesity suggests that these patients may have increased biliary excretion of digoxin possibly owing to a higher expression of P-gp in the liver. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - November 22, 2023 Category: Drugs & Pharmacology Source Type: research
Population Pharmacokinetic/Pharmacodynamic Analysis of the Glucokinase Activator PB201 in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus: Facilitating the Clinical Development of PB201 in China
This study aims to develop a population PK/pharmacodynamic (PD) model for PB201 using the pooled data from nine phase I/II clinical trials conducted in non-Chinese healthy volunteers and a T2DM population and to predict the PK/PD profile of PB201 in a Chinese T2DM population. We developed the PK/PD model using the non-linear mixed-effects modeling approach. All runs were performed using the first-order conditional estimation method with interaction. The pharmacokinetics of PB201 were well fitted by a one-compartment model with saturable absorption and linear elimination. The PD effects of PB201 on reducing the fasting plas...
Source: Clinical Pharmacokinetics - November 20, 2023 Category: Drugs & Pharmacology Source Type: research
